Pooled safety analysis from two phase III studies of secukinumab in paediatric patients with moderate-to-severe plaque psoriasis up to week 52

被引：0

作者：

Sticherling, M. ^{[1
]}

Nikkels, A. F. ^{[2
]}

Hamza, A. M. ^{[3
]}

Kwong, P. ^{[4
]}

Ortmann, C. -E. ^{[5
]}

Papanastasiou, P. ^{[5
]}

Forrer, P. ^{[5
]}

Keefe, D. ^{[6
]}

机构：

[1] Univ Klinikum Erlangen, Hautklin, Erlangen, Germany

[2] Univ Liege, Dept Dermatol, CHU Sart Tilman, Liege, Belgium

[3] Alexandria Univ, Alexandria, Egypt

[4] Solut Adv Res, Jacksonville, FL USA

[5] Novartis Pharmaceut, Basel, Switzerland

[6] Novartis Pharmaceut, E Hanover, NJ USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 186卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P49

引用

页码：E39 / E40

页数：2

共 50 条

[1] Efficacy and safety of secukinumab by age group in patients with moderate-to-severe plaque psoriasis: Pooled analysis of 4 phase III trials
Draelos, Zoe
Kempers, Steven
Helfrich, Yolanda
Meng, Xiangyi
Fox, Todd
Nyirady, Judit
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB247 - AB247
[2] Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
Koerber, Andreas
Papavassilis, Charis
Bhosekar, Vaishali
Reinhardt, Maximilian
DRUGS & AGING, 2018, 35 (02) : 135 - 144
[3] Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
Andreas Körber
Charis Papavassilis
Vaishali Bhosekar
Maximilian Reinhardt
Drugs & Aging, 2018, 35 : 135 - 144
[4] Evaluation of Malignancy Risk With Secukinumab Treatment in a Pooled Analysis of 10 Clinical Studies of Moderate-to-Severe Plaque Psoriasis up to 52 Weeks
van de Kerkhof, P.
Strober, B.
Karpov, A.
Huang, J.
Cooper, S.
Fox, T.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S33 - S33
[5] Evaluation of Infections With Secukinumab in a Pooled Analysis of 10 Clinical Studies of Moderate-to-Severe Plaque Psoriasis
Tsai, T.
Blauvelt, A.
Karpov, A.
Huang, J.
Cooper, S.
Fox, T.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S33 - S33
[6] Secukinumab was efficacious in the treatment of moderate to severe plaque psoriasis on the head and neck: Pooled analysis of phase III studies
Kircik, Leon
JosephFowler
Weiss, Jonathan
Meng, Xiangyi
Guana, Adriana
Nyirady, Judit
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB252 - AB252
[7] Secukinumab efficacy and safety in Asian subjects with moderate to severe plaque psoriasis: Pooled analysis from the FIXTURE and ERASURE phase III clinical studies
Lee, Jeung-Hoon
Morita, Akimichi
Tsai, Tsen-Fang
Zheng, Eugene
Ko, Luke
Fox, Todd
Langley, Richard
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB249 - AB249
[8] Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
van de Kerkhof, Peter C. M.
Griffiths, Christopher E. M.
Reich, Kristian
Leonardi, Craig L.
Blauvelt, Andrew
Tsai, Tsen-Fang
Gong, Yankun
Huang, Jiaqing
Papavassilis, Charis
Fox, Todd
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (01) : 83 - +
[9] Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
Nina Magnolo
Külli Kingo
Vivian Laquer
John Browning
Adam Reich
Jacek C. Szepietowski
Deborah Keefe
Philemon Papanastasiou
Weibin Bao
Pascal Forrer
Manmath Patekar
Pediatric Drugs, 2022, 24 : 377 - 387
[10] Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study
Magnolo, Nina
Kingo, Kulli
Laquer, Vivian
Browning, John
Reich, Adam
Szepietowski, Jacek C.
Keefe, Deborah
Papanastasiou, Philemon
Bao, Weibin
Forrer, Pascal
Patekar, Manmath
PEDIATRIC DRUGS, 2022, 24 (04) : 377 - 387

← 1 2 3 4 5 →